EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> MorphoSys obtained an option on Vivoryon Therapeutics’ small molecule QPCTL inhibitors in the treatment of cancer. The deal sees MorphoSys commit to take a €15 million ($17 million) stake in Vivoryon as part of an upcoming financing round. Statement

> Acacia Pharma detailed plans to refile for approval of Barhemsys in the third quarter. The disclosure of the plan follows a meeting with the FDA. Release  

> UniQure shared 36-week data on its hemophilia B gene therapy AMT-061. The mean FIX activity in the three patients treated with AMT-061 was 45% of normal. Statement 

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

> Freeline posted 12-month data on its hemophilia B gene therapy. FIX activity came in around 40%, but Freeline hopes to ramp that up to 50% to 150% once it optimizes the dose. Release 

> Vasopharm raised €9.5 million to fund work in support of a planned filing for approval of ronopterin. The German company is testing the allosteric iNOS inhibitor in traumatic brain injury patients. Statement 

> Redx Pharma sold a pan-RAF inhibitor to Jazz Pharmaceuticals for $3.5 million upfront. The deal for the preclinical oncology program includes $203 million in milestones. Release 

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.